Background: Hepatitis c virus (HCV) is a serious worldwide problem which has a great impact on health status in the field of liver diseases with an estimation of 170 million people infected worldwide. HCV infection is gaining increasing attention as a global health problem, with approximately 3% of the world's population infected. Egypt reports the highest prevalence of HCV worldwide, ranging from 6% to more than 40% with an average of 13.8%. Today, many direct-acting antivirals (DAAs) are available with encouraging results in terms of both virologic response and safety. Objectives: The aim of this study was to evaluate the prevalence of SVR (12-24 weeks) in Egyptian patients with different Child-Pough classification, the complications and its frequency during, and after treatment with combination of antiviral agents. Patients and Methods: This study was performed at Internal Medicine Department, Ahmed Maher Teaching Hospital, Cairo, Egypt,. The study included 650 patients with chronic hepatitis C that were categorized into 3 groups according to Child-Pugh classification as follows: Group A: included 300 patients with Child-Pugh score of 5-6 points, Group B: included 300 patients with child-Pugh score of 7-9 points, and Group C: included 50 patients with Child-Pugh score of 10-15 points Patients enrolled in the study were prospectively evaluated as outpatients by the study staff after 4, 8, 12 weeks and at 12 and 24 weeks post- treatment. Results: There was a statistically highly significant difference in PCR before treatment (100% +ve) and after treatment (100% -ve)at 1st mo,3rd mo, 6th mo in group A. There was a statistically highly significant difference in PCR before treatment (100% +ve) and after treatment -ve at 1st mo,3rd mo 6th mo (100%, 100%, 91.6% respectively) in group B; and there was a statistically highly significant difference in PCR before treatment (100% +ve) and after treatment –ve at 1st mo,3rd mo, 6th mo (100%, 82%, 54% respectively) in gourp C. Throughout the study, most of the patients were responders (95.1% achieved SVR12). Conclusion: Use of SOF-DCV in patients with chronic HCV-G4 proved to be safe and associated with a high SVR12 rate, in patients with different stages of fibrosis.